Hemostatic agent and method
Inventors
Roberts, Keith A. • Burban, John Henry • Zia, Majid • Spearman, Michael R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9649482-B2
Publication Date
2017-05-16
Expiration Date
Abstract
One aspect of the invention is a method of treating a wound to clot blood. A sponge material is applied to the wound. The sponge comprises a starch having hemostatic properties and at least one binding agent. The sponge may further comprise a porous, flexible material.
Core Innovation
The disclosed invention relates to hemostatic sponges and bandage arrangements that use starch or polysaccharide hemostatic agents. The hemostatic agent includes modified pregelatinized potato starch and amylopectin, including modified pregelatinized amylopectin, and is incorporated into porous flexible sponge material and other porous flexible structures.
The invention addresses the problem of applying hemostatic material in difficult anatomical locations and of providing a hemostatic material that is flexible. Compared with powder delivery, the disclosed bandage arrangements are easier to apply in difficult anatomical locations and create flexible hemostatic material that can bend without cracking.
The disclosed bandage arrangements also include a wound-pressing structure using an adhesive portion and a depressible plunger. A plurality of plunger tabs interlock with the plunger to latch the plunger after it is depressed such that the plunger remains in a depressed position without a human maintaining continued pressure on the plunger.
In further configurations, a hemostatic agent is attached directly or indirectly to the plunger and is protected by a removable cover until use. The hemostatic agent is available in selected physical forms such as particles, gauze, mesh, sponge, fibers, film, or a porous solid, and is selected from starch and polysaccharide materials including various pregelatinized and modified starches and amylopectin derivatives.
Claims Coverage
The independent claims are directed to a wound-pressing bandage with an adhesive portion and a latchable depressible plunger, with optional attachment and configuration features that enable hemostatic agent integration. Across the independent claims, two main inventive feature sets are present: a latchable depressible plunger actuated after attachment and maintained without continued human pressure, and integration of a hemostatic agent with the wound-pressing structure, including specified forms and starch/polysaccharide selections.
Adhesive portion with latchable depressible plunger
A bandage comprising an adhesive portion to attach the bandage to the skin of a patient, a depressible plunger operable to be depressed after the bandage has been attached to apply downward pressure on a wound, and a plurality of plunger tabs operable to interlock with the plunger to latch the plunger after the plunger has been depressed such that the plunger remains in a depressed position without a human maintaining continued pressure on the plunger, wherein the plurality of plunger tabs are coupled to the adhesive portion.
Downward-pressure depressible plunger latched by interlocking plunger tabs
A bandage comprising a depressible plunger operable to be depressed after the bandage has been attached to a patient, the depressible plunger operable to apply downward pressure on a wound when depressed, and a plurality of plunger tabs operable to interlock with the plunger to latch the plunger after the plunger has been depressed such that the plunger remains in a depressed position without a human maintaining continued pressure on the plunger.
Hemostatic agent attached to the plunger (directly or indirectly)
A bandage further including a hemostatic agent attached directly or indirectly to the plunger.
Hemostatic agent in selected physical forms
The hemostatic agent is selected from particles, gauze, mesh, sponge, fibers, film, or a porous solid.
Hemostatic agent selected from polysaccharide/starch forms
The hemostatic agent comprises one or more selected starch/polysaccharide materials chosen from polysaccharide, starch, pregelatinized starch, modified pregelatinized starch, modified pregelatinized potato starch, amylopectin, potato starch, pregelatinized potato starch, pregelatinized amylopectin, and modified pregelatinized amylopectin.
Overall, the independent claims cover a wound-pressing bandage that applies downward pressure using a depressible plunger that is latched by interlocking plunger tabs, eliminating the need for continued human pressure. Further claim coverage specifies integration of a hemostatic agent with the plunger, including direct or indirect attachment, selectable physical forms, and starch/polysaccharide selections including pregelatinized and modified starches and amylopectin derivatives.
Stated Advantages
Easier application in difficult anatomical locations compared with powder delivery.
Flexible hemostatic material that can bend without cracking.
Documented Applications
Hemostatic treatment for bleeding wounds and wound exudate.
Use in oral surgery and gums.
Use for nosebleeds.
Use for deep wounds with catheters.
Interested in licensing this patent?